Loading...
News & Insights2020-02-18T15:42:30+00:00

Healthcare Agency Roundtable

Thought Leadership|

In this edition of Med Ad News, executive management from healthcare communications agencies and networks participate in the special feature Healthcare Agency Roundtable. Precision’s Jackie DeAngelis, Andrew Cournoyer, and Isabella Sergio weigh in on topics ranging from the COVID-19 pandemic to diversity, equity and inclusion.

(more…)

Self-Reported Health Care Resource Utilization in Clinical Trials

Thought Leadership|

Real-world data are important sources within health care resource utilization (HCRU) research, but these databases often are repurposed for this use rather than custom designed. Some researchers are beginning to collect HCRU data within the context of clinical trials, with the intention to address research questions of interest, rather than relying solely on data salvaged from insurance claims or electronic health records.

(more…)

Value-Based Care Can Do More

Thought Leadership|

The Home Health Value-Based Purchasing Model (HHVBP) was a five-year project from the Center for Medicare & Medicaid Innovation designed to improve the quality and cost effectiveness of home health. In late 2021, the Centers for Medicare & Medicaid Services announced that it would be expanding the HHVBP nationwide.

(more…)

Cancer Care in the Misinformation Age

Thought Leadership|

While misinformation has plagued the public health field for decades, social media has amplified its spread. Both medical and public health leaders are beginning to develop strategies for this public health crisis. Precision’s Cynthia Miller lists three ways pharma companies can work with stakeholders to address cancer misinformation using evidence-based approaches.

(more…)

HHS Rule Not Only Empowers Patients but Also Benefits Other Industry Stakeholders

Thought Leadership|

As the use of real-world data in the health care system grows, a recent HHS rule giving patients electronic access to their data stands to have a huge impact on this area. Precision’s Dominic Galante weighs in on the 21st Century Cures Act, including a discussion of stakeholders that could benefit from the rule and the potential for innovations within the health care system.

(more…)

Pfizer and Takeda deals put spotlight back on value-based pricing programs

Thought Leadership|

Over the last decade, value-based reimbursement models have garnered a mountain of interest, but challenges in building a data infrastructure that can identify outcome metrics and logistics to dispense payments have largely relegated these models to anecdotal status. Recent deals by Pfizer and Takeda may indicate a step forward. Precision’s Ryan Cox weighs in on the evolving state of value based reimbursement models.

(more…)

Load More Posts